{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:50:47Z","timestamp":1791175847363,"version":"4.1.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0134395","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T18:31:01Z","timestamp":1440786661000},"page":"e0134395","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":64,"title":["Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients"],"prefix":"10.1371","volume":"10","author":[{"given":"Julia","family":"Dietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Susser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Berkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Perner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"issue":"Suppl 1","key":"ref1","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"C Sarrazin","year":"2012","journal-title":"Journal of hepatology"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"R Bartenschlager","year":"2013","journal-title":"Nature reviews Microbiology"},{"issue":"9956","key":"ref3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"E Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"16","key":"ref5","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"20","key":"ref6","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"20","key":"ref7","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"9954","key":"ref8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"M Manns","year":"2014","journal-title":"Lancet"},{"issue":"21","key":"ref9","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"17","key":"ref11","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"9883","key":"ref13","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"KV Kowdley","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJMc1307641","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"369","author":"E Lawitz","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"ES Svarovskaia","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"O Lenz","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DA DeGoey","year":"2014","journal-title":"Journal of medicinal chemistry"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"RA Fridell","year":"2011","journal-title":"Hepatology"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"RA Fridell","year":"2010","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"EJ Lawitz","year":"2012","journal-title":"Journal of hepatology"},{"issue":"Supplement S1","key":"ref22","first-page":"1128A","article-title":"Baseline and Post-baseline Resistance Analyses of Phase 2\/3 Studies of Ledipasvir\/Sofosbuvir \u00b1 RBV Hepatology","volume":"60","author":"C Sarrazin","year":"2014","journal-title":"Baseline and Post-baseline Resistance Analyses of Phase 2\/3 Studies of Ledipasvir\/Sofosbuvir \u00b1 RBV Hepatology"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"EF Donaldson","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1053\/j.gastro.2011.07.019","article-title":"Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24\u201372 weeks","volume":"141","author":"C Sarrazin","year":"2011","journal-title":"Gastroenterology"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/JVI.02778-12","article-title":"Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients","volume":"87","author":"J Dietz","year":"2013","journal-title":"Journal of virology"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.05636-11","article-title":"Virologic escape during danoprevir (ITMN-191\/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution","volume":"56","author":"SR Lim","year":"2012","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"DJ Bartels","year":"2013","journal-title":"Journal of virology"},{"key":"ref28","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"TA Hall","year":"1999","journal-title":"Nucleic Acids Symposium"},{"issue":"5325","key":"ref29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.277.5325.570","article-title":"Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA","volume":"277","author":"AA Kolykhalov","year":"1997","journal-title":"Science"},{"issue":"5424","key":"ref30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"V Lohmann","year":"1999","journal-title":"Science"},{"key":"ref31","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","author":"O Lenz","year":"2014","journal-title":"Journal of hepatology"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"F McPhee","year":"2012","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"S498","DOI":"10.1016\/S0168-8278(14)61390-8","article-title":"Lack of impact of baseline resistance-associated variants (RAVs) on treatment outcome in the aviator study with ABT-450\/r, ABT-333 and ABT-267, +\/- ribavirin","volume":"60","author":"P Krishnan","year":"2014","journal-title":"Journal of hepatology"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3\/4A Protease Inhibitor ABT-450","volume":"59","author":"T Pilot-Matias","year":"2015","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"W Kati","year":"2015","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A","volume":"59","author":"P Krishnan","year":"2015","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"S1","key":"ref37","first-page":"218A","article-title":"L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions","volume":"60","author":"ES Svarovskaia","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"X Tong","year":"2014","journal-title":"The Journal of infectious diseases"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2014.07.016","article-title":"Treatment of HCV infection with the novel NS3\/4A protease inhibitors","volume":"18C","author":"A De Luca","year":"2014","journal-title":"Current opinion in pharmacology"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy","volume":"49","author":"S Gaudieri","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"T Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"J Vermehren","year":"2012","journal-title":"Best practice & research Clinical gastroenterology"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"F Poordad","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"AS Lok","year":"2014","journal-title":"Journal of hepatology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","article-title":"Antiviral therapy of hepatitis C in 2014: do we need resistance testing?","volume":"105","author":"MD Schneider","year":"2014","journal-title":"Antiviral research"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvvir +\/\u2212 RBV","volume":"62","author":"C Sarrazin","year":"2015","journal-title":"Journal of hepatology"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0168-8278(15)30154-9","article-title":"Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 Ally-1 study","volume":"62","author":"F Poordad","year":"2015","journal-title":"Journal of hepatology"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0168-8278(15)30168-9","article-title":"A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotyope 1 infection without cirrhosis: Optimist-1","volume":"62","author":"P Kwo","year":"2015","journal-title":"Journal of hepatology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116C","author":"C Sarrazin","year":"2015","journal-title":"Antiviral research"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"F McPhee","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0168-8278(15)30158-6","article-title":"A phase-3 open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2","volume":"62","author":"E Lawitz","year":"2015","journal-title":"Journal of hepatology"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Y Suzuki","year":"2013","journal-title":"Journal of hepatology"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","author":"F Suzuki","year":"2012","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(15)30155-0","article-title":"Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1\u20134 in HIV-HCV coinfection: The Ally-2 study","volume":"62","author":"DL Wyles","year":"2015","journal-title":"Journal of hepatology"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"DR Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"S1","key":"ref56","first-page":"1134A","article-title":"Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials","volume":"60","author":"P Krishnan","year":"2014","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0134395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:21:02Z","timestamp":1589041262000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0134395"}},"subtitle":[],"editor":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0134395","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}